This biomarker template is not required for accreditation purposes but may be used to facilitate compliance with CAP Accreditation Program checklist requirements.
Explanatory Notes

A. Immunohistochemical Analysis
Because of the advent of small-molecule kinase inhibitor therapy in the treatment of GIST (see the following), it has become imperative to distinguish GIST from its histologic mimics, mainly leiomyoma, leiomyosarcoma, schwannoma, and desmoid fibromatosis. 1, 2 Immunohistochemistry is instrumental in the workup of GIST. For the initial work up of GIST, a basic immunohistochemical panel including CD117 (KIT), DOG1 (Ano1), Desmin, S100 protein and CD34 is recommended. GISTs are immunoreactive for KIT (CD117) (approximately 95%) and/or DOG1(>99%). [3] [4] [5] KIT immunoreactivity is usually strong and diffuse but can be more focal in unusual cases ( Figure 1, A and B ). It is not unusual for GISTs to exhibit dot-like perinuclear staining (Figure 1 , C), while less commonly, some cases exhibit membranous staining (Figure 1, D) . These patterns do not clearly correlate with mutation type or response to therapy. Most KIT-negative / DOG1 positive GISTs are gastric or extra-visceral GISTs and almost invariably harbor a platelet-derived growth factor receptor A (PDGFRA) mutation. 6 DOG1 expression is not related to mutational status in GISTs, and it may be a useful marker to identify a subset of patients with CD117-negative GISTs, who might benefit from targeted therapy 4, 5 . Approximately 70% of GISTs are positive for CD34, 30% to 40% are positive for smooth muscle actin, 5% are positive for S100 protein (usually focal), 5% are positive for desmin (usually focal), and 1% to 2% are positive for keratin (weak/focal). 7 Since succinate dehydrogenase (SDH)-deficient GISTs have specific implications (see the following), it is recommended to screen all gastric GISTs for loss of SDH by immunohistochemistry, usually best accomplished by staining for SDHB, which is loss in all subtypes of SDH-deficient GISTs. [8] [9] [10] [11] Mutations in SDHA are detected in 30% of SDH-deficient GISTs and loss of expression of SDHA specifically identifies tumors with SDHA mutations; other SDH-deficient GISTs show normal (intact) cytoplasmic staining for SDHA. 12, 13 Patients with SDH-deficient GIST should be referred to a genetic counselor for appropriate work up. 
B. Molecular Analysis
Approximately 75% of GISTs possess activating mutations in the KIT gene, whereas another 10% have activating mutations in the PDGFRA gene. [1] [2] [3] [4] These mutations result in virtually full-length KIT proteins that exhibit ligandindependent activation. KIT and PDGFRA each contain 21 exons. However, mutations cluster within "hotspots": exons 9, 11, 13, and 17 in KIT, and exons 12, 14, and 18 in PDGFRA (Figure 2 ). About 5% to 10% of GISTs appear to be negative for both KIT and PDGFRA mutations. The most recent NCCN Task Force on GIST strongly encourages that KIT and PDGFRA mutational analysis be performed if tyrosine kinase inhibitors (TKIs) are considered as part of the treatment plan for unresectable or metastatic disease and that mutational analysis be considered for patients with primary disease, particularly those with high-risk tumors. KIT and PDGFRA mutation status can be determined easily from paraffin-embedded tissue. Secondary or acquired mutations can be associated with development of tumor resistance in the setting of long-term imatinib mesylate treatment. These are usually point mutations that occur most commonly in KIT exons 13, 14, and 17. 5 The clinical utility of these mutations is an evolving concept, but it is important not to confuse them with the primary or initial mutation in GIST.
Recent studies focusing on the molecular classification of GISTs recognized two major subgroups : succinate dehydrogenase (SHD)-competent and SDH-deficient GISTs, both of which can arise in the sporadic or familiar setting. 6.7 SDH-competent GISTs include tumors with mutations of KIT and PDGFRA as well of a subset of wildtype GISTs with mutations mainly in NF1 and BRAF genes. On the other hand, SDH-deficient GISTs include tumors with a genetic alteration in any of the SDH subunits leading to SDH dysfunction.
SDH-deficient
GISTs represent approximately 8% of GISTs and comprise some sporadic cases, the majority of pediatric GISTs, and two forms of syndromic GISTs (Carney triad and Carney-Stratakis syndrome). 6 SDH is a mitochondrial enzyme comprising four subunits (SDHA, SDHB, SDHC and SDHD) that is involved in the Krebs cycle. Genetic alteration of any of the four subunits results in SDH dysfunction and subsequent loss of SDHB expression by immunohistochemistry. SDH deficient GISTs arise almost exclusive in the stomach, affect predominantly female patients and tend to manifest at a young age. Pathologic features associated with SDHdeficient tumors include multinodular and/or plexiform growth pattern, epithelioid morphology, lymphovascular invasion, nodal involvement and frequent metastasis to the liver and peritoneum. Importantly, germline mutations in the genes coding for any of the SHD subunits can lead to paragangliomas/pheochromocytomas, SDH-deficient renal cell carcinoma and pituitary tumors in addition to GISTs. Since SDH-deficient GISTs typically require germline genetic testing possibly including family members as well as possible surveillance for paragangliomas/pheochromocytomas, it is recommended that all gastric GISTs be screened for loss of SDHB by immunohistochemistry. All patients with SDH-deficient GISTs identified by loss of SDHB stain should be referred to a genetic counselor. * Refers to exons involved most frequently by secondary/acquired mutations. KIT and PDGFRA are excellent targets for small-molecule tyrosine kinase inhibitors, and two compounds of this class, imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland) and sunitinib malate (Sutent, Pfizer Pharmaceuticals, New York, New York), have shown efficacy in clinical trials and have been approved by the US Food and Drug Administration for the treatment of GIST. 8-10 SDH-deficient GISTs are usually resistant to imatinib but may have a higher probability of response to sunitinib. 6 Because different tyrosine kinase inhibitors (TKIs) may have more efficacy in genetic subsets of GIST, oncologists may want to know the mutation status of each GIST, because this may impact which drug each patient should receive. 1, 11 Secondary resistance mutations may also affect drug selection as their significance is further defined.
C. KIT Mutational Analysis
The most common mutations affect the juxta membrane domain encoded by exon 11 (two-thirds of GIST). These mutations include in-frame deletions, substitutions, and insertions. Deletions (in particular codon 557 and/or 558) are associated with shorter progression free and overall survival. [1] [2] [3] [4] [5] [6] The vast majority of exon 11-mutated GISTs are located in the stomach. 5 About 7% to 10% of the tumors harbor mutations in the extracellular domain encoded by exon 9 (most commonly insAY502-503). 5,7 Exon 9-mutant GISTs arise predominantly in the small bowel and have reduced sensitivity to imatinib which could be overcome by using higher doses. 5 Primary mutations in the activation loop (exon 17) and ATP binding region (exon 13) are uncommon (1%). The majority of these mutations are substitutions. 8 KIT exon 8 mutations are extremely rare (0.15%). 9 Secondary or resistance mutations occur commonly in tumors harboring primary exon 11 mutations. These newly acquired secondary mutations are always located in exons encoding tyrosine kinase domain (exons 13, 14, 17). 10 More than 80% of KIT-negative GISTS have PDGFRA mutations. The majority of PDGFRA-mutated GISTs arise in the stomach, usually with epithelioid or mixed epithelioid and spindle cell morphology and often with myxoid stromal changes. 1,2 PDGFRA-mutated GISTs tend to have a lower risk of recurrence. 1, 3 Activation of PDGFRA is seen in GISTs harboring mutations in juxta membranous domain (exon 12), the ATP binding domain (exon 14), or the activation loop (exon 18). 1 
H. Dissection Method:
While in majority of cases GIST samples show tumor percentage (%) well above the analytical sensitivity of Sanger sequencing (>50% neoplastic cell percentage/20% to 25% mutant allele percentage), in cases of mutation analysis of treated samples, careful macro/microdissection may be necessary to avoid false negative results.
I. Reporting Nomenclature
Consistent gene mutation nomenclature is essential for efficient and accurate reporting. 1 Following are examples as recommended by Human Genome Variation Society (HGVS) for description of variant changes. 2 It is also preferred that protein alterations are mentioned in the report in addition to genomic coordinates. 
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